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We performed a cross-sectional, population-based survey of persons 20 years of age and
older living in Cairo and surrounding rural villages. The purpose was to describe glycaemic
control and the prevalence of microvascular and neuropathic complications among
Egyptians with diagnosed diabetes, previously undiagnosed diabetes, impaired glucose
tolerance, and normal glucose tolerance. A total of 6052 households were surveyed. The
response rate was 76 % for the household survey and 72 % for the medical examination.
Among people with previously diagnosed diabetes, mean haemoglobin A1c was 9.0 %.
Forty-two per cent had retinopathy, 21 % albuminuria, and 22 % neuropathy. Legal
blindness was prevalent (5 %) but clinical nephropathy (7 %) and foot ulcers (1 %) were
uncommon in persons with diagnosed diabetes. Among people with diagnosed diabetes,
microvascular and neuropathic complications were associated with hyperglycaemia.
Retinopathy was also associated with duration of diabetes; albuminuria with hypertension
and hypercholesterolaemia; and neuropathy with age, female sex, and hypercholesterol-
aemia. Albuminuria was as common in people with previously undiagnosed diabetes
(22 %) as those with diagnosed disease (21 %). Mean haemoglobin A1c was lower (7.8 %)
and retinopathy (16 %) and neuropathy (14 %) were less prevalent in people with
previously undiagnosed disease. Ocular conditions, blindness, and neuropathy were
prevalent in the non-diabetic population. The microvascular and neuropathic complications
of diabetes are a major clinical and public health problem in Egypt.  1998 John Wiley &
Sons, Ltd.
Diabet. Med. 15: 1045–1051 (1998)
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Introduction
During the past decade, studies on the epidemiology of
diabetes mellitus have been reported from Eastern
Mediterranean countries.1,2 Few have reported on the
epidemiology of the complications of diabetes and none
has been population-based.1 Data from clinical series
have suggested that the majority of patients have
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relatively short duration of diabetes but that long-term
complications occur at rates similar to those reported in
Western countries.1 The purpose of this report is to
describe glycaemic control and the prevalence of diabetic
eye, kidney, and neuropathic complications in a popu-
lation-based sample of people aged 20 years and older
living in Cairo and surrounding rural villages.
Patients and Methods
The survey methods have been described previously.3
In brief, the target population for urban sampling
comprised people 20 years of age and older living in
Cairo, Egypt and that for rural sampling was people aged
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20 years and older living in three agricultural villages in
Kaliubia, a rural delta region approximately 30 miles
north of Cairo. In both urban and rural areas, trained
teams of social workers visited each selected household
and one person was randomly selected to participate in
the study.
Each subject answered a questionnaire, underwent
physical examination, and had a random capillary whole
blood glucose level measured with a portable reflectance
meter (One Touch II, LifeScan Inc., Milpitas, CA, USA).
All respondents at high risk for diabetes (random capillary
whole blood glucose >5.6 mmol l21) and a random
sample of those at low risk for undiagnosed diabetes
(random capillary whole blood glucose <5.6 mmol l−1
were invited to have a more extensive medical examin-
ation done at the Diabetes Institute in Cairo.
In the household examination, we identified 6052
eligible households. In these households, 4918 people
completed the household questionnaire and 4620 com-
pleted the questionnaire and had a capillary glucose
level measured (76 % response rate). On the basis of
the results of the capillary glucose, 2021 people were
invited to the Diabetes Institute for more detailed
examination (1351 at higher risk for diabetes and a
sample of 670 people at lower risk). Of those, 1451
came and completed the examination (72 % response
rate). Among people at higher risk (capillary whole blood
glucose levels >5.6 mmol l21), the response rate was
72 % (976/1351). Of the sample of 670 of the 3269
people at lower risk for diabetes (capillary whole blood
glucose levels ,5.6 mmol l21), 475 came and completed
the medical examination (71 % response rate).
Medical examinations were conducted by trained
physicians, nurses, and technicians. All subjects provided
informed consent. The examination included measure-
ment of fasting serum glucose and serum glucose 2 h
after a 75-g oral glucose load, haemoglobin A1c, urinal-
ysis, serum creatinine, urine albumin, and urine creatin-
ine. It also included measurement of sitting blood pressure
with a mercury sphygmomanometer. An opthalmologist
measured visual acuity and performed a slit lamp
examination (Model M-IIB, Marco Inc., Jacksonville, FL,
USA), applanation tonometry, a dilated eye examination
and retinal photography through pharmacologically
dilated pupils using a nonmydriatic retinal camera
(CR4-45NM, Canon Inc., Tokyo, Japan). In addition a
standardized foot examination and quantitative assess-
ment of vibratory sensation using a forced choice
algorithm (Vibration II, Physitemp Instruments Inc., Clifton
NJ, USA) were performed. Written protocols for all
procedures were developed and testing during the pilot
phase of the study.
Urine dipstick testing (Chemstrip 8 urine test strips,
Boehringer Mannheim Diagnostics, Indianapolis, IN,
USA), serum glucose, total cholesterol, and serum
creatinine measurements (Kodak Ektachem DTSCII, East-
man Kodak Co., Rochester, NY, USA) were done in the
laboratory at the Diabetes Institute. Duplicate serum
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glucose, total cholesterol, and serum creatinine levels
were measured at the Central Health Laboratories with
the same methodologies. Haemoglobin A1c was measured
with affinity column chromatography (Pierce Scientific
Corp., Rockford, IL, USA), urine albumin was measured
by radioimmunoassay (Diagnostic Products Corp., Los
Angeles, CA, USA), and urine creatinine was measured
by a colorimetric Jaffe alkaline picrate method (Bio-
Merieux, France) at the Central Health Laboratories in
Cairo. Strict laboratory quality control was maintained
throughout the study.
Diabetes and impaired glucose tolerance were defined
according to WHO criteria.4 Fundus photographs were
read by the Wisconsin Reading Center (Madison, WI,
USA). Albuminuria was defined as an albumin-to-
creatinine ratio >100 mg g21. This level was chosen to
reflect ‘high’5 or ‘clinically significant’6 microalbuminuria.
Prospective observational studies have demonstrated that
subjects with a median urinary albumin excretion of
approximately 100 mg 24 h21 are significantly more
likely than those with lesser degrees of microalbuminuria
to develop clinical nephropathy within 5 years.7 Periph-
eral polyneuropathy was defined empirically as a thres-
hold for vibratory sensation >4 SD above that of the
non-diabetic study population 20–44 years of age. This
represents individuals with vibratory sensation thresholds
significantly greater than those of the young generally
healthy Egyptian population. Hypertension was defined
as history of hypertension or systolic blood pressure
>160 mmHg or diastolic blood pressure >95 mmHg.
Data were entered in duplicate at the Diabetes Institute
and analysed with EPI-Info (Centers for Disease Control
and Prevention, Atlanta, GA, USA) and SAS (SAS Institute
Inc., Cary, NC, USA) software.
Statistical Analyses
People were classified as having diagnosed diabetes,
previously undiagnosed diabetes, impaired glucose toler-
ance, or normal glucose tolerance on the basis of their
histories of diabetes and the results of the oral glucose
tolerance tests. The population was treated as an
unweighted cross-sectional cohort. In Tables 1–4 both
means and 95 % confidence intervals (95 % CI) are
presented. Logistic regression models were used to
assess variables independently associated with diabetic
retinopathy, albuminuria, and neuropathy in people with
diagnosed diabetes. Explanatory variables included age,
duration of diabetes, sex, socio-economic status (SES)
and residence (upper SES and urban residence, lower
SES and urban residence, and rural residence), haemo-
globin A1c, hypertension, hypercholesterolaemia, and
cigarette smoking. Results are presented as odds ratios
(OR) and 95 % confidence intervals.
Results
People with abnormal glucose tolerance were older and
more likely to be female than those with normal glucose
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tolerance. Of those with diagnosed diabetes, 83 % were
>45 years of age and 65 % were female. Of those with
previously undiagnosed diabetes, 77 % were >45 years
of age and 69 % were female. Of people with IGT, 54 %
were >45 years of age and 59 % were female. Of those
with normal glucose tolerance, 44 % were >45 years of
age and 57 % were female.
Haemoglobin A1c levels were higher among people
with diagnosed diabetes than among those with pre-
viously undiagnosed diabetes (Table 1). Mean haemo-
globin A1c levels were 9.3 % in those with insulin-treated
diabetes and 8.9 % among people with diagnosed
diabetes not treated with insulin. Among people with
diabetes, haemoglobin A1c levels tended to decrease
with age. Haemoglobin A1c levels were not different
between the groups with IGT and normal glucose
tolerance and tended to increase slightly with age.
Legal blindness (defined as best corrected visual acuity
in the better eye ,6/60) was present in 5 % of those
with diagnosed diabetes and diabetic retinopathy was
present in 42 % (Table 2). In multivariate analysis using
logistic regression, diabetic retinopathy was associated
with longer duration of diabetes (per 10 years) (OR =
1.37, 95 % CI 1.09, 1.73) and higher haemoglobin A1c
(per unit) (OR = 1.15, 95 % CI 1.03, 1.27). Corneal
disease (defined as any central or peripheral nebula or
leukoma) was prevalent in all groups (Table 2). Cataract
(defined as any nuclear or cortical cataract) and intra-
ocular hypertension (defined as intraocular pressure
.21 mmHg in either eye) were more prevalent in people
with diabetes than in those with IGT or normal glucose
tolerance (Table 2). Compared to people without diabetes,
the relative risks of both cataract and intraocular hyperten-
sion were greater among younger people with diabetes.
Sixty-two per cent of people with diagnosed diabetes,
47 % of those with previously undiagnosed diabetes,
27 % of those with IGT, and 22 % of those with normal
glucose tolerance had evidence of the eye diseases
assessed in this study (Table 2).
Albuminuria, defined as an albumin-to-creatinine ratio
of >100 mg g-creatinine21 in the presence of ,10 red
blood cells per high-powered field and no leukocytes
on dipstick testing, was more prevalent in people with
diagnosed and undiagnosed diabetes than in those
with IGT and normal glucose tolerance (Table 3). The
prevalence of albuminuria was 25 % among people with
Table 1. Mean haemoglobin A1c levels and 95 % confidence interval by age and diabetes status
Age DxDM UndxDM IGT Normal
(n = 364) (n = 114) (n = 127) (n = 697)
A1c % (CI) A1c % (CI) A1c % (CI) A1c % (CI)
HbA1c
20–44 9.2 (8.5, 9.9) 8.4 (7.5, 9.3) 5.4 (5.2, 5.7) 5.3 (5.2, 5.4)
451 9.0 (9.7, 9.2) 7.7 (7.3, 8.1) 5.5 (5.4, 5.7) 5.4 (5.3, 5.6)
Total 9.0 (8.7, 9.2) 7.8 (7.5, 8.2) 5.5 (5.3, 5.6) 5.4 (5.3, 5.4)
CI, 95 % confidence interval; DxDM, diagnosed diabetes; UndxDM; previously undiagnosed diabetes.
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diabetes and hypertension (history of hypertension and/or
systolic BP >160 and/or diastolic BP >95 mmHg), 20 %
among people with hypertension only, 17 % among
people with diabetes only, and 5 % among people with
neither diabetes nor hypertension. In multivariate analysis,
albuminuria was associated with hypertension (OR =
2.72, 95 % CI 1.21, 6.11), higher haemoglobin A1c (per
unit) (OR = 1.15, 95 % CI 0.99, 1.34), and higher total
cholesterol (per 0.26 unit) (OR = 1.04, 95 % CI 1.00,
1.09). Clinical nephropathy, defined as an albumin-to-
creatinine ratio of >300 mg g-creatinine21, was present
in 7 % of those with diagnosed and undiagnosed diabetes
and was approximately four times as prevalent in people
with diabetes as in those with IGT and normal glucose
tolerance (Table 3). Very few subjects had evidence of
renal insufficiency (serum creatinine >180 mmol l21).
Peripheral polyneuropathy, defined as a threshold for
vibratory sensation >4 SD above that of the non-diabetic
population 20–44 years of age, was more common in
people with diabetes, and the prevalence increased with
age (Table 4). In multivariate analysis, neuropathy was
associated with older age (per 10 years) (OR = 2.01,
95 % CI 1.43, 2.82), female sex (OR = 2.34, 95 % CI
1.17, 4.69), higher haemoglobin A1c (per unit) (OR =
1.14, 95 % CI 1.02, 1.28), and higher total cholesterol
(per 0.26 unit) (OR = 1.04, 95 % CI 1.00, 1.08).
Peripheral polyneuropathy was also common in older
people without diabetes. Foot ulcers were present in less
than 1 % of subjects but were more prevalent in people
with diabetes than in those without (Table 4).
Discussion
We report cross-sectional population-based data on
glycaemic control and the prevalence of microvascular
and neuropathic complications and their risk factors
among Egyptians with diabetes mellitus, previously
undiagnosed diabetes mellitus, impaired glucose toler-
ance, and normal glucose tolerance. To our knowledge,
such population-based data have not been reported
previously from the Eastern Mediterranean Region.
Our finding that haemoglobin A1c was highest among
subjects with diagnosed diabetes, higher than among
those with previously undiagnosed diabetes, probably
reflects the more severe hyperglycaemia of the former.
Our finding of higher haemoglobin A1c levels in younger
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Table 2. Prevalence of legal blindness, retinopathy, corneal opacity, cataract, intraocular hypertension, and any eye disease, and
95 % confidence intervals by age and diabetes status
Age DxDM UndxDM IGT Normal
% (CI) % (CI) % (CI) % (CI)
Legal blindness (n = 390) (n = 124) (n = 138) (n = 756)
20–44 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
451 5.9 (3.3, 8.5) 2.1 (0.0, 5.0) 6.8 (1.0, 12.5) 4.2 (2.1, 6.4)
Total 4.9 (2.7, 7.0) 1.6 (0.0, 3.8) 3.6 (0.5, 6.7) 1.9 (0.9, 2.8)
Diabetic retinopathy (n = 287) (n = 89) (n = 103) (n = 600)
20–44 47.2 (33.7, 60.6) 13.0 (0.0, 26.8) 0.0 (0.0, 0.0) 2.2 (0.7, 3.7)
451 40.2 (33.9, 46.5) 16.7 (7.7, 25.7) 4.4 (0.0, 10.5) 3.0 (0.8, 5.2)
Total 41.5 (35.8, 47.2) 15.7 (8.2, 23.3) 1.9 (0.0, 4.6) 2.5 (1.3, 3.7)
Corneal opacity (n = 381) (n = 122) (n = 138) (n = 748)
20–44 4.5 (0.0, 9.6) 6.9 (0.0, 16.1) 3.2 (0.0, 7.5) 2.4 (0.9, 3.8)
451 9.5 (6.3, 12.8) 19.4 (11.3, 27.4) 14.9 (6.8, 23.0) 15.0 (11.1, 18.9)
Total 8.7 (5.8, 11.5) 16.4 (9.8, 23.0) 9.4 (4.5, 14.3) 7.9 (6.0, 9.8)
Cataract (n = 371) (n = 121) (n = 137) (n = 742)
20–44 10.4 (3.1, 17.8) 10.3 (0.0, 21.4) 4.8 (0.0, 10.0) 3.1 (1.4, 4.8)
451 45.4 (39.8, 51.0) 39.1 (29.2, 49.1) 38.4 (27.2, 49.5) 37.0 (31.7, 42.2)
Total 39.1 (34.1, 44.0) 32.2 (23.9, 40.6) 22.6 (15.6, 29.6) 17.8 (15.0, 20.5)
Intraocular hypertension (n = 381) (n = 120) (n = 136) (n = 741)
20–44 4.5 (0.0, 9.4) 6.9 (0.0, 16.1) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
451 3.2 (1.2, 5.1) 3.3 (0.0, 7.0) 1.4 (0.0, 4.0) 2.2 (0.6, 3.8)
Total 3.4 (1.6, 5.2) 4.2 (0.6, 7.7) 0.7 (0.0, 2.2) 0.9 (0.2, 1.6)
Any eye diseasea (n = 395) (n = 125) (n = 143) (n = 765)
20–44 44.9 (33.2, 56.7) 31.0 (14.2, 47.9) 6.2 (0.3, 12.0) 7.0 (4.6, 9.4)
451 65.3 (60.2, 70.5) 52.1 (42.1, 62.1) 45.5 (34.3, 56.6) 41.4 (36.2, 46.7)
Total 61.8 (57.0, 66.6) 47.2 (38.4, 56.0) 27.3 (20.0, 34.6) 22.2 (19.3, 25.2)
aAny disorder noted in table.
CI, 95 % confidence interval; DxDM, diagnosed diabetes; UndxDM, previously undiagnosed diabetes.
Table 3. Prevalence of albuminuria and clinical nephropathy, and 95 % confidence intervals by age and diabetes status
Age DxDM UndxDM IGT Normal
% (CI) % (CI) % (CI) % (CI)
Albuminuriaa (n = 210) (n = 73) (n = 61) (n = 389)
20–44 24.2 (9.6, 38.9) 12.5 (0.0, 28.7) 8.3 (0.0, 19.4) 6.3 (3.1, 9.5)
451 20.3 (14.4, 26.3) 24.6 (13.4, 35.7) 13.9 (2.6, 25.2) 11.4 (6.6, 16.3)
Total 21.0 (15.4, 26.5) 21.9 (12.4, 31.4) 11.5 (3.5, 19.5) 8.5 (5.7, 11.3)
Clinical nephropathyb (n = 210) (n = 73) (n = 61) (n = 389)
Total 6.7 (3.3, 10.0) 6.8 (1.1, 12.6) 1.6 (0.0, 4.8) 1.8 (0.5, 3.1)
aUrine albumin: creatinine ratio > 100 mg g21.
bUrine albumin: creatinine ratio > 300 mg g21.
CI, 95 % confidence interval; DxDM, diagnosed diabetes; UndxDM, previously undiagnosed diabetes.
people with diagnosed and undiagnosed diabetes prob-
ably reflects the admixture of people with Type 1 and
Type 2 diabetes, with more Type 1 disease in the
younger group.8 Blood glucose control in the Egyptian
population with diagnosed diabetes was similar to that
observed among conventionally treated subjects in the
Diabetes Control and Complications Trial.9 Our haemo-
globin A1c findings are consistent with epidemiologic
studies that have reported fasting glucose levels.10
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The prevalence of legal blindness in all our subjects,
as has been reported in other populations, increased
with age. In the Wisconsin Epidemiologic Study of
Diabetic Retinopathy (WESDR), Klein estimated that 2 %
of people with Type 2 diabetes were blind11 and in a
study from Poole, Houston estimated that 1 % of insulin-
taking diabetic people and 2 % of non-insulin-taking
diabetic people were legally blind.12 The high prevalence
of legal blindness in the Egyptian population, including
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Table 4. Prevalence of peripheral polyneuropathy and foot ulcers, and 95 % confidence intervals by age and diabetes status
Age DxDM UndxDM IGT Normal
% (CI) % (CI) % (CI) % (CI)
Neuropathya (n = 384) (n = 125) (n = 140) (n = 750)
20–44 11.8 (4.1, 19.4) 0.0 (0.0, 0.0) 1.6 (0.0, 4.7) 0.5 (0.0, 1.1)
451 24.1 (19.3, 28.8) 17.7 (10.1, 25.3) 17.1 (8.6, 25.6) 13.4 (9.7, 17.1)
Total 21.9 (17.7, 26.0) 13.6 (7.6, 19.6) 10.0 (5.0, 15.0) 6.1 (4.4, 7.9)
Foot ulcers (n = 389) (n = 123) (n = 140) (n = 753)
Total 0.8 (0.0, 1.6) 0.8 (0.0, 2.4) 0.0 (0.0, 0.0) 0.1 (0.4, 0.4)
aDefined as Vibratron reading > 4SD above that for the normal population 20–44 years of age.
CI, 95 % confidence interval; DxDM, diagnosed diabetes; UndxDM, previously undiagnosed diabetes.
non-diabetic groups, probably reflects a greater preva-
lence of other conditions associated with visual impair-
ment and, possibly, less access to eye care.
Using retinal photography as a criterion for diagnosing
diabetic retinopathy, we found that 42 % of subjects
with diagnosed diabetes and 16 % of subjects with
previously undiagnosed diabetes had diabetic retino-
pathy. Among those with diagnosed diabetes, retinopathy
was associated with duration of diabetes and hypergly-
caemia. The rates of retinopathy are quite similar to the
crude prevalence rates of diabetic retinopathy found in
other epidemiologic studies that have employed fundus
photography.13–17 Our finding that 16 % of those with
previously undiagnosed diabetes had diabetic retinopathy
suggests that the duration of diabetes before clinical
diagnosis was approximately 8 years.18 In other popu-
lations with previously undiagnosed diabetes, the duration
of diabetes before clinical diagnosis has been reported
to be 9 to 12 years.19 These data suggest that in Egypt
the severity of hyperglycaemia is less or the duration of
diabetes from onset to diagnosis is shorter than in rural
Australia or southern Wisconsin. Low measurable rates
of diabetic retinopathy in the Egyptian populations with
impaired glucose tolerance and normal glucose tolerance
may reflect misclassification of drusen or hypertensive
retinopathy, misclassification of diabetes status, or
regression of diabetes towards normal glucose tolerance.
We found a high prevalence of corneal disease which
appeared to be non-differentially distributed among
diabetic and non-diabetic subjects. This is likely to be
due to a high prevalence of traumatic injury and trachoma
in the population. There have been few previous studies
of corneal problems in persons with diabetes. In the
Beaver Dam Eye Study (Wisconsin, USA), there was no
difference between people with and without diabetes in
regards to corneal abnormalities.11 Previous clinic-based
studies of Type 1 diabetic subjects have, however,
indicated a higher prevalence of subtle corneal
changes.20,21
Cataracts were common in all our subjects (albeit
more common in the diabetic groups) and the prevalence
increased with age. This prevalence is lower than
observed in Wisconsin where approximately 27 % of
subjects with Type 1 diabetes and 86 % of subjects with
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Type 2 diabetes had cataracts.11 This may be due to the
younger age distribution of the population. Ascertainment
bias may have also contributed to the difference.
Our glaucoma rates in the diabetic (4 %) and non-
diabetic (1 %) groups were similar to those reported in
other population-based studies.11
Microalbuminuria was prevalent in our diabetic sub-
jects and low levels (30–99 mg g21) were prevalent in
the entire population regardless of glucose tolerance
(data not shown). These findings are consistent with a
Saudi Arabian clinic-based study in which 42 % of
diabetic subjects and 13 % of non-diabetic controls had
microalbuminuria but fewer than 10 % of diabetic
subjects and none of the non-diabetic subjects had
urinary albumin excretion rates greater than 100 mg
24h21.22 This suggests that factors transiently increase
albuminuria such as uncontrolled hypertension or exer-
cise may be prevalent in the populations with and
without diabetes.23 Rates of albuminuria (urine albumin-
to-creatinine ratio >100 mg g21) were not different
between groups with diagnosed and undiagnosed dia-
betes, approximately twice as high as in non-diabetic
subjects. Among people with diagnosed diabetes, albumi-
nuria was associated with hypertension, hypercholesterol-
aemia and hyperglycaemia. The role of hypertension is
underscored by the fact that the prevalence of albuminuria
was highest among persons with diabetes and hyperten-
sion, essentially the same among persons with hyperten-
sion only and persons with diabetes only, and lowest
among persons with neither diabetes nor hypertension.
We found that the prevalence of clinical nephropathy
(7 %) was three-fold higher than in subjects without
diabetes (2 %) but was two- to three-times lower than
the crude prevalence of clinical nephropathy in the
Saudi Arabian clinic-based study (13 %)22 and three-fold
lower than observed in southern Wisconsin (21 %).24
The reason for these differences is not clear. The higher
prevalence of clinical nephropathy in diabetic subjects
in Saudi Arabia may reflect selection bias associated
with a clinic-based study. The higher prevalence of
clinical nephropathy in diabetic subjects in Wisconsin
may reflect differences in the distributions of age,
duration, and severity of diabetes. Decreased genetic
susceptibility to nephropathy or decreased survival of
INTERNATIONAL SCENE
subjects with nephropathy in Egypt might also explain
these differences.
Twenty-two per cent of our subjects with diagnosed
diabetes had distal symmetrical sensorimotor polyneuro-
pathy based on quantitative vibration perception testing.
Among people with diagnosed diabetes, neuropathy was
associated with older age, female sex, hyperglycaemia,
and hypercholesterolemia. Recent cross-sectional studies
have provided population-based estimates of the fre-
quency of diabetic neuropathy ranging from 16 % to
42 %.25–28 Our finding of an intermediate prevalence of
polyneuropathy in the population with undiagnosed
diabetes suggests that diabetes has existed for some time
before clinical diagnosis. The prevalence of neuropathy
of 6 % in the non-diabetic population may represent
neuropathy due to other causes.29
The prevalence of foot ulcers was low in our diabetic
population. In British population-based studies, the
prevalence of current diabetic foot ulcers on examination
ranges from 1 % to 3 %.26,30 Differences in the distri-
butions of age, duration, and severity of diabetes between
the populations, differences in the prevalence or severity
of neuropathy, increased attention to care of the foot
associated with Egyptian cultural practices, or decreased
survival of subjects with foot ulcers in Egypt might
explain these differences.
In summary, our data are consistent with those of
population-based studies from around the world and
confirm that diabetes and its complications are now
major clinical and public health problems in Egypt.
There are, however, intriguing differences including a
relatively low prevalence of clinical nephropathy and
foot ulcers in the diabetic population and a high
prevalence of other ocular conditions, blindness, and
peripheral polyneuropathy in the Egyptian population
without diabetes. These warrant further exploration.
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